$67.1 Million is the total value of Syncona Portfolio Ltd's 4 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AUTL | AUTOLUS THERAPEUTICS PLCspon ads | $49,738,112 | -2.1% | 21,346,829 | 0.0% | 74.10% | -3.2% | |
| ACHL | ACHILLES THERAPEUTICS PLCsponsored ads | $10,087,979 | -3.7% | 11,086,909 | 0.0% | 15.03% | -4.8% | |
| FRLN | Sell | FREELINE THERAPEUTICS HLDGSsponsored ads | $6,217,990 | +64.3% | 1,466,507 | -0.0% | 9.26% | +62.4% |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $1,074,289 | -15.7% | 1,377,294 | 0.0% | 1.60% | -16.6% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Syncona Holdings Limited #1
- Syncona Limited #2
- Syncona Investment Management Limited #3
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-01
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AUTOLUS THERAPEUTICS PLC | 8 | Q3 2023 | 76.6% |
| ACHILLES THERAPEUTICS PLC | 8 | Q3 2023 | 53.1% |
| FREELINE THERAPEUTICS HLDGS | 8 | Q3 2023 | 27.4% |
| ADAPTIMMUNE THERAPEUTICS PLC | 8 | Q3 2023 | 4.9% |
View Syncona Portfolio Ltd's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Freeline Therapeutics Holdings plc | March 25, 2022 | 37,862,147 | 62.3% |
| Nightstar Therapeutics plc | March 14, 2019 | 13,203,922 | 39.0% |
View Syncona Portfolio Ltd's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13D/A | 2024-02-22 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| 13F-HR | 2024-02-01 |
| SC 13D/A | 2023-11-24 |
| 13F-HR | 2023-11-01 |
| SC 13D/A | 2023-10-18 |
| 13F-HR | 2023-07-27 |
| 13F-HR | 2023-05-12 |
| SC 13G/A | 2023-02-14 |
View Syncona Portfolio Ltd's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.